TPSTHealthcare · BiotechnologyThe 1 Wall Street analysts covering Tempest Therapeutics, Inc. hold a median 12-month price target of $7 — +927.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 13 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Tempest Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (91): Smaller than most of the companies we track.
Volatility (6): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TPST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +927.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $11 → $7.00 |
| 22 Jan 2026 | HC Wainwright & Co. | Upgrade | Buy | $11 |
| 22 Jan 2026 | HC Wainwright & Co. | Upgrade | Buy | — |
| 10 Apr 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 10 Apr 2025 | Scotiabank | Downgrade | Sector Perform | — |
| 28 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Mar 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 13 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2024 | Piper Sandler | Maintains | Overweight | — |
| 10 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 June 2024 | Piper Sandler | Reiterates | Overweight | — |
| 20 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Mar 2024 | Scotiabank | Initiates | Sector Outperform | — |
| 13 Mar 2024 | Scotiabank | Initiates | Sector Outperform | — |
| 12 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Feb 2024 | Jefferies | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TPST appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Oct 2026, Tempest Therapeutics, Inc. returned −94.1% against +18.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 77% of US stocks
Cheaper than 98% of US stocks
Cheaper than 67% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 2% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Tempest Therapeutics, Inc. has a market value of $12.5M and an enterprise value of $18.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$40.5M.
Free cash flow in the twelve months to 30 June 2026: −$20.7M.
Trailing P/E: −0.1×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Tempest Therapeutics, Inc. employs 4 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Tempest Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Tempest Therapeutics announced the appointment of John W. Frederick to its board of directors, adding financial and capital markets expertise.
Why it matters — TPST watchers may note the addition of financial and capital markets experience to the company’s board.
Tempest Therapeutics announced that Nancy Freda-Smith, a global finance leader, has been appointed to its board of directors and will serve as Chair of the Audit Committee. The appointment was announced on September 23, 2026.
Why it matters — Adding an experienced global finance executive to lead the Audit Committee strengthens Tempest's corporate governance and financial oversight at the board level.
Tempest Therapeutics shares traded sharply higher in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd.
Why it matters — The option agreement with Hebei Senlang represents a new strategic partnership for Tempest that watchers of the company would want to track.
Tempest Therapeutics announced it has secured an exclusive option to license a clinical-stage CD7-targeted lentiviral in vivo CAR-T platform. This transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year.
Why it matters — A TPST watcher would care because this expands Tempest's in vivo CAR-T capabilities and deepens its pipeline in the CD7-targeted oncology space ahead of the planned clinic entry of its existing platform.
Tempest Therapeutics announced a private placement of up to $7.5 million, consisting of $2.5 million in upfront proceeds and up to approximately $5 million in potential aggregate gross proceeds upon the full exercise of warrants.
Why it matters — TPST watchers would care because this private placement provides the company with additional capital to fund its operations, with further potential proceeds contingent on warrant exercise.
The 1 Wall Street analysts covering Tempest Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $7 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Tempest Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tempest Therapeutics, Inc. 45 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Oct 2026, Tempest Therapeutics, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +927.4% from the last close, and Ticker Nerd's factor model ranks Tempest Therapeutics, Inc. 45 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Tempest Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TPST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.
Tempest Therapeutics, Inc. returned -94.1% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Tempest Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cancer therapies through targeted and immune-mediated mechanisms.
The most recent item we track (GlobeNewsWire, 14 Oct 2026): "Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise". Tempest Therapeutics announced the appointment of John W. Frederick to its board of directors, adding financial and capital markets expertise.
Tempest Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cancer therapies through targeted and immune-mediated mechanisms. The company’s current pipeline centers on small molecule and cell therapy programs designed to address multiple oncology indications, including solid tumors and hematologic cancers. Its portfolio includes advanced investigational candidates that aim to modulate tumor biology, enhance anti-tumor immune responses, and broaden the reach of next-generation cell therapy approaches. Tempest Therapeutics also works with partners on certain clinical programs, reflecting a business model centered on drug development, clinical research, and translational oncology. Based in Brisbane, California, Tempest Therapeutics Inc. operates within the biopharmaceutical sector as a research-driven company advancing experimental treatments toward clinical evaluation.
CEO Dr. Matthew Angel Ph.D. · 4 employees · United States · https://www.tempesttx.com
